|
|
Volumn 337, Issue 6101, 2012, Pages 1450-1451
|
|
Despite setbacks, optimism on drugs for hepatitis C
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABT 072;
ABT 267;
ABT 333;
ABT 450;
ABT O72;
ACH 1625;
ANTIVIRUS AGENT;
ASUNAPREVIR;
BI 207127;
BMS 791325;
BMS 986094;
DACLATASVIR;
DANOPREVIR;
FALDAPREVIR;
GS 5885;
GS 7977;
GS 9256;
GS 9451;
GSK 2336805;
IDX 184;
IDX 719;
MERICITABINE;
MK 5172;
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;
RIBAVIRIN;
RNA DIRECTED RNA POLYMERASE INHIBITOR;
SETROBUVIR;
SIMEPREVIR;
TEGOBUVIR;
UNCLASSIFIED DRUG;
VANIPREVIR;
VX 222;
ALPHA INTERFERON;
ENZYME INHIBITOR;
IL28B PROTEIN, HUMAN;
INTERLEUKIN DERIVATIVE;
DRUG;
HEALTH MONITORING;
HEPATITIS;
OPTIMIZATION;
ALLELE;
DRUG COST;
DRUG INDUSTRY;
GENOTYPE;
HEALTH CARE COST;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
PRIORITY JOURNAL;
SHORT SURVEY;
TREATMENT DURATION;
CHEMISTRY;
CLINICAL TRIAL (TOPIC);
DRUG COMBINATION;
DRUG EFFECT;
ENZYMOLOGY;
GENETICS;
NOTE;
HEPATITIS C VIRUS;
ANTIVIRAL AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG THERAPY, COMBINATION;
ENZYME INHIBITORS;
GENOTYPE;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON-ALPHA;
INTERLEUKINS;
RIBAVIRIN;
|
|
EID: 84866455042
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.337.6101.1450 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|
